Lidocain/Prilocain Idetec and associated names
- Procedure started
- Under evaluation
- CHMP opinion
- European Commission final decision
Table of contents
Overview
On 14 October 2021, the European Medicines Agency completed a review of Lidocain/Prilocain Idetec and associated names following a disagreement among EU Member States regarding its authorisation. The Agency concluded that the benefits of Lidocain/Prilocain Idetec could not be shown to outweigh its risks, and the marketing authorisation could not be granted in Denmark or in the other Member State of the EU where the company has applied for a marketing authorisation (in this case, the Netherlands).
In November 2021 EMA started a re-examination of its opinion at the request of the company; however, the re-examination procedure was stopped as the applicant decided to withdraw its application for marketing authorisation.
Key facts
|
About this medicine
|
|
|---|---|
| Approved name |
Lidocain/Prilocain Idetec and associated names
|
| International non-proprietary name (INN) or common name |
|
| Associated names |
Lidocaïne / Prilocaïne 5% Focus, Crème
|
|
About this procedure
|
|
|---|---|
| Current status |
European Commission final decision
|
| Reference number |
EMEA/H/A-29(4)/1506
|
| Type |
Article 29(4) referrals
This type of referral is triggered when there is a disagreement between Member States regarding a marketing authorisation application being evaluated in a mutual-recognition or decentralised procedure, on the grounds of a potential serious risk to public health. |
| Authorisation model |
Nationally authorised product(s)
|
| Decision making model |
CHMP-EC
|
|
Key dates and outcomes
|
|
|---|---|
| CHMP opinion date |
14/10/2021
|
All documents
Opinion provided by Committee for Medicinal Products for Human Use
Lidocain/Prilocain Idetec Referral Article-29(4) - Annex II (PDF/91.49 KB)
First published: 12/04/2022
Lidocain/Prilocain Idetec Referral Article-29(4) - Annex I (PDF/63.95 KB)
First published: 12/04/2022
Lidocain/Prilocain Idetec Referral Article-29(4) - Public Assessment Report including divergent positions to CHMP Opinion (PDF/540.69 KB)
First published: 12/04/2022
EMA/CHMP/344182/2021
Description of documents published
Please note that some of the listed documents apply only to certain procedures.
- Overview - lay-language summary of the stage of the procedure
- Notification – a letter from a Member State, the European Commission or the marketing authorisation holder requesting the initiation of the procedure
- Scientific background – further background information from the triggering Member State on the issues leading to the initiation of the procedure (if applicable)
- List of questions – questions agreed by the Committee requesting further information from the marketing authorisation holder(s) / applicant(s) to evaluate the issues identified
- Timetable for the procedure – agreed timeframe to respond to the list of questions, to assess the issues and to adopt a conclusion
- List of medicines concerned by the procedure – medicine(s) / active substance(s) concerned, and marketing authorisation holder(s) / applicant(s)
- List of questions to be addressed by the stakeholders – call for data to be submitted by stakeholders (e.g. healthcare professionals, patient organisations, individual patients) (if applicable)
- Stakeholder submission form – form to be used by stakeholders to submit data (if applicable)
- Scientific conclusions – scientific conclusions of the PRAC and/or CHMP and/or CMDh
- Assessment report – PRAC or CHMP assessment and conclusions on the issues investigated, including divergent positions (if applicable)
- Divergent positions – divergent positions of the CHMP or CMDh members for pharmacovigilance procedures (if applicable)
- Changes to the summary of product characteristics, labelling and package leaflet (amended sections or fully revised version) (if applicable)
- Condition(s) to the marketing authorisation(s) – condition(s) for the safe and effective use of the medicine(s) (if applicable)
- Condition for lifting the suspension – condition to be fulfilled for the suspension of the marketing authorisation(s) to be lifted (if applicable)
- Timetable for implementation of CMDh position – agreed timeframe to submit and finalise the variation(s) implementing the outcome of the procedure (if applicable)
Note that older documents may have different titles.
News
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 202228/01/2022
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 8-11 November 202112/11/2021
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 202115/10/2021